๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Acute Myeloid Leukemia, in Relapse
Clinical trial register · United States · industry-sponsored

Acute Myeloid Leukemia, in Relapse Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
Texas 4 North Carolina 3 Florida 2 New York 2 California 2
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
7 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies
NCT06906380Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, in Relapsed or Refractory, MDS (Myelodysplastic Syndrome)
ARCE Therapeutics, Inc.
Observational
49
North Carolina, Texas
2026-03-15
Recruiting
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT04716452Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory, Refractory/Relapse Acute Myeloid Leukemia
Keystone Nano, Inc
Phase 1
15
Virginia
2025-10-01
Recruiting
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
NCT06552416Acute Myeloid Leukemia, in Relapse, MDS
Marker Therapeutics, Inc.
Phase 1
40
California, Florida, Kansas
2025-06-16
Recruiting
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
NCT06680752Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
ARCE Therapeutics, Inc.
Phase 1/2
49
North Carolina, Texas
2025-05-20
Active, closed
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT05546580Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Oryzon Genomics S.A.
Phase 1
50
Arizona, Florida, Maryland, Massachusetts, New Jersey, New York, North Carolina, Oregon
2022-11-14
Recruiting
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
NCT05190471Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Bio-Path Holdings, Inc.
Phase 1
48
California, New York, Texas
2022-08-16
Recruiting
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05211570Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia
AB Science
Phase 1/2
78
Texas
2022-06-01
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/acute-myeloid-leukemia-in-relapse

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.